Federal Register / Vol. 71, No.
142 / Tuesday, July 25, 2006 / Notices 42097
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: July 17, 2006.
Randall W. Lutter,
Associate Commissioner for Policy and
Planning.
[FR Doc. E6–11772 Filed 7–24–06; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Obstetrics and Gynecology Devices
Panel of the Medical Devices Advisory
Committee; Notice of Meeting
AGENCY: Food and Drug Administration,
HHS.
ACTION: Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of the Committee: Obstetrics
and Gynecology Devices Panel of the
Medical Devices Advisory Committee.
General Function of the Committee:
To provide advice and
recommendations to the agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on August 29, 2006, from 8 a.m. to
5 p.m.
Location: Hilton Washington DC
North/Gaithersburg, Montgomery
Ballroom, 620 Perry Pkwy.,
Gaithersburg, MD 20877.
Contact: Michael Bailey, Center for
Devices and Radiological Health (HFZ–
470), Food and Drug Administration,
9200 Corporate Blvd., Rockville, MD
20850, 301–594–1180 or FDA Advisory
Committee Information Hotline, 1–800–
741–8138 (301–443–0572 in the
Washington, DC area), code
3014512524. Please call the Information
Line for up-to-date information on this
meeting.
Agenda: The committee will discuss,
make recommendations, and vote on a
premarket approval application for a
non-invasive device for use as a
complement to clinical breast
examination in asymptomatic women
between the ages of 30 to 39.
Background information, including the
agenda and questions for the committee,
will be available to the public one
business day before the meeting on the
sroberts on PROD1PC70 with NOTICES
Internet at http://www.fda.gov/cdrh/
panel (click on ‘‘Upcoming CDRH
Advisory Panel/Committee Meetings’’).
Procedure: Interested persons may
present data, information, or views,
VerDate Aug<31>2005 18:02 Jul 24, 2006 Jkt 208001
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before August 22, 2006.
Oral presentations from the public will
be scheduled between approximately
8:15 a.m. and 8:45 a.m., and between
approximately 3:30 p.m. and 4 p.m.
Time allotted for each presentation may
be limited. Those desiring to make
formal oral presentations should notify
the contact person and submit a brief
statement of the general nature of the
evidence or arguments they wish to
present, the names and addresses of
proposed participants, and an
indication of the approximate time
requested to make their presentation on
or before August 22, 2006.
Persons attending FDA’s advisory
committee meetings are advised that the
agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact AnnMarie
Williams at least 7 days in advance of
the meeting at 301–827–7291.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: July 17, 2006.
Randall W. Lutter,
Associate Commissioner for Policy and
Planning.
[FR Doc. E6–11773 Filed 7–24–06; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
General and Plastic Surgery Devices
Panel of the Medical Devices Advisory
Committee; Notice of Meeting
AGENCY: Food and Drug Administration,
HHS.
ACTION: Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). At least one portion of the
meeting will be closed to the public.
Name of Committee: General and
Plastic Surgery Devices Panel of the
Medical Devices Advisory Committee.
General Function of the Committee:
To provide advice and
recommendations to the agency on
FDA’s regulatory issues.
PO 00000 Frm 00023 Fmt 4703 Sfmt 4703 E:\FR\FM\25JYN1.SGM
Date and Time: The meeting will be
held on August 24, 2006, from 8 a.m. to
5 p.m., and on August 25, 2006, from 9
a.m. to 5 p.m.
Location: Holiday Inn, Walker/
Whetstone Rooms, Two Montgomery
Village Ave., Gaithersburg, MD.
Contact Person: David Krause, Center
for Devices and Radiological Health
(HFZ–410), Food and Drug
Administration, 9200 Corporate Blvd.,
Rockville, MD 20850, 301–594–3090,
ext. 141, or FDA Advisory Committee
Information Line, 1–800–741–8138
(301–443–0572 in the Washington, DC
area), code 3014512519. Please call the
Information Line for up-to-date
information on this meeting.
Agenda: On August 24, 2006, the
committee will discuss, make
recommendations, and vote on a
premarket approval application (PMA)
for an injectable device intended for use
in the correction of lipoatrophy of the
face in HIV (human immunodeficiency
virus) positive patients and a second
PMA for the same device intended for
use as a filler material to restore soft
tissue facial contours such as nasolabial
folds. On August 25, 2006, the
committee will discuss and make
recommendations on the
reclassification, to Class II, of a Class III
medical device: Cyanoacrylate tissue
adhesive. Background information for
this meeting, including the agenda and
questions for the committee, will be
available to the public 1 business day
before the meeting on the Internet at
http://www.fda.gov/cdrh/panel (click on
‘‘Upcoming CDRH Advisory Panel/
Committee Meetings’’). Material for the
August 24 and 25 sessions will be
posted on August 23, 2006.
Procedure: On August 24, 2006, from
8 a.m. to 5 p.m., and on August 25,
2006, from 9:30 a.m. to 5 p.m., the
meeting is open to the public. Interested
persons may present data, information,
or views, orally or in writing, on issues
pending before the committee. Written
submissions may be made to the contact
person on or before August 10, 2006. On
August 24, 2006, oral presentations from
the public will be scheduled between
approximately 8:30 a.m. and 9 a.m.,
approximately 11:45 a.m. and 12:15
p.m., approximately 1:45 p.m. and 2:15
p.m., and approximately 3:45 p.m. and
4:15 p.m. On August 25, 2006, oral
presentations from the public will be
scheduled between approximately 11
a.m. and 12 noon. Time allotted for each
presentation may be limited. Those
desiring to make formal oral
presentations should notify the contact
person and submit a brief statement of
the general nature of the evidence or
arguments they wish to present, the
25JYN1
 42098 Federal Register / Vol. 71, No. 142 / Tuesday, July 25, 2006 / Notices
names and addresses of proposed
participants, and an indication of the
approximate time requested to make
their presentation on or before August
10, 2006.
Closed Committee Deliberations: On
August 25, 2006, from 9 a.m. to 9:30
a.m., the meeting will be closed to
permit FDA to present to the committee
trade secret and/or confidential
commercial information (5 U.S.C.
552b(c)(4)) relating to pending issues
and applications.
Persons attending FDA’s advisory
committee meetings are advised that the
agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact AnnMarie
Williams, Conference Management
Staff, at 301–827–7291, at least 7 days
in advance of the meeting.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C., app. 2).
Dated: July 17, 2006.
Randall W. Lutter,
Associate Commissioner for Policy and
Planning.
[FR Doc. E6–11775 Filed 7–24–06; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Nonprescription Drugs Advisory
Committee; Notice of Meeting
AGENCY: Food and Drug Administration,
HHS.
ACTION: Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: Nonprescription
Drugs Advisory Committee.
General Function of the Committee:
To provide advice and
recommendations to the agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on September 25, 2006, from 8 a.m.
to 5 p.m.
Location: Hilton Hotel Washington
sroberts on PROD1PC70 with NOTICES
DC North/Gaithersburg, The Ballrooms,
620 Perry Pkwy., Gaithersburg, MD. The
hotel phone number is 301–977–8900.
Contact Person: Darrell Lyons, Center
for Drug Evaluation and Research (HFD
VerDate Aug<31>2005 19:44 Jul 24, 2006 Jkt 208001
21), Food and Drug Administration,
5600 Fishers Lane (for express delivery,
5630 Fishers Lane, rm. 1093) Rockville,
MD 20857, 301–827–7001, FAX: 301–
827–6778, e-mail: lyonsd@cder.fda.gov
or FDA Advisory Committee
Information Line, 1–800–741–8138
(301–443–0572 in the Washington, DC
area) code 3014512541. Please call the
Information Line for up to date
information on this meeting.
Agenda: The committee will consider
issues related to the analysis and
interpretation of consumer behavior
studies conducted to support marketing
of nonprescription drug products. The
background material will become
available no later than the day before
the meeting and will be posted under
the Nonprescription Drugs Advisory
Committee (NDAC) docket site at http://
www.fda.gov/ohrms/dockets/ac/
acmenu.htm. (Click on the year 2006
and scroll down to NDAC meetings.)
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before September 11, 2006.
Oral presentations from the public will
be scheduled between approximately 1
p.m. and 2 p.m. Time allotted for each
presentation may be limited. Those
desiring to make formal oral
presentations should notify the contact
person and submit a brief statement of
the general nature of the evidence or
arguments they wish to present, the
names and addresses of proposed
participants, and an indication of the
approximate time requested to make
their presentation before September 11,
2006.
Persons attending FDA’s advisory
committee meetings are advised that the
agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Darrell Lyons
at least 7 days in advance of the
meeting.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: July 17, 2006.
Randall W. Lutter,
Associate Commissioner for Policy and
Planning.
[FR Doc. E6–11774 Filed 7–24–06; 8:45 am]
BILLING CODE 4160–01–S
PO 00000 Frm 00024 Fmt 4703 Sfmt 4703 E:\FR\FM\25JYN1.SGM
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel, Spore in GI
Cancer.
Date: September 11–13, 2006.
Time: 5 p.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: Doubletree Hotel, 8120 Wisconsin
Ave., Bethesda, MD 20814.
Contact Person: Shamala K. Srinivas, PhD,
Scientific Review Administrator, Research
Programs Review Branch, Division of
Extramural Activities, National Cancer
Institute, 6116 Executive Boulevard, Room
8123, Bethesda, MD 20892. 301–594–1224.
ss537t@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: July 18, 2006.
Anna Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 06–6452 Filed 7–24–06; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
25JYN1